Related Experiment Video
Updated: Jul 21, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
High Prevalence of Hepatitis C Virus Infection in Chronic Hemodialysis Patients
1Clinical Hospital of the Federal University of Paraná and Center of Nefrology Nações Curitiba/Paraná, Brazil.
Insights
Hepatitis C virus (HCV) is common in hemodialysis patients. Higher blood transfusions and longer dialysis duration are linked to HCV RNA positivity, stressing infection control measures.
Area of Science:
- Nephrology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection is prevalent in hemodialysis (HD) patients.
- Transmission routes include blood transfusions, duration of HD, and nosocomial spread within dialysis units.
Purpose of the Study:
- To determine the cross-sectional frequency of HCV infection in HD patients.
- To evaluate associations between HCV infection and patient demographics, clinical, and biochemical features.
Main Methods:
- Serum samples from 74 HD patients tested for anti-HCV antibodies using third-generation ELISA.
- Positive samples confirmed with recombinant immunoblot assay and HCV RNA detection via PCR.
- Data collected: age, gender, HD duration, blood transfusions, and ALT levels.
Main Results:
- 29.4% (29/74) of patients were anti-HCV positive by ELISA.
- HCV RNA was detected in 69% (20/29) of anti-HCV positive patients.
- HCV RNA-positive patients had significantly more blood transfusions and longer HD duration (p<0.0001).
- Mean serum ALT levels were significantly higher in HCV RNA-positive patients (p<0.0001).
Conclusions:
- HCV infection is frequent in hemodialysis patients.
- Increased blood transfusions and longer dialysis duration are associated with HCV RNA positivity.
- Emphasizes the critical need for stringent infection control, hygiene, and equipment sterilization in dialysis units to combat HCV transmission.
Abstract:
Hepatitis C virus (HCV) infection is very common among hemodialysis (HD) patients. Transmission of infection in this setting has been related to the number of blood transfusions, the duration of hemodialysis and to nosocomial transmission of virus in the dialysis unit. We conducted a study of 74 HD patients to determine the frequency of HCV at a single point in time (cross-sectional analysis), and to evaluate the association between HCV infection and patients' demographic, clinical and biochemical features. Serum samples were tested for anti-HCV antibodies using a third-generation enzyme-linked immunosorbent assay (ELISA). In the case of a positive result, third-generation recombinant immunoblot and HCV RNA detection by polymerase chain reaction (PCR) tests were performed. Collected data included the patient's age, gender, time on HD, number of blood transfusions and serum alanine aminotransferase (ALT) activity. Twenty-nine patients (29/74.4%) were found to be HCV positive using a third-generation ELISA assay. Of these 29 patients, 27 were also positive by recombinant immunoblot assay and 2 patients had indeterminate results. In the anti-HCV ELISA-positive subgroup, 20 (69%) of the 29 patients had detectable HCV RNA. The HCV RNA-positive patients had received more blood transfusions (15&plusm;3 vs. 5&plusm;1 units of packed red blood cells, p<0.0001) and had been on HD for a longer period of time than the HCV RNA-negative patients (65&plusm;32 vs. 32&plusm;29 months, p<0.0001). Mean serum ALT levels were significantly higher in the HCV RNA positive group (30&plusm;18 vs. 15&plusm;9, p<0.0001). We were unable to determine the most likely mode of transmission in our unit, but these results emphasize the need for strict adherence to blood collecting and handling precautions, careful attention to hygiene in the dialysis units, and sterilization of dialysis machines in order to properly combat this frequent infection.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Chronic Kidney Disease II: Clinical Manifestations
Hepatitis
Viral Hepatitis I: Introduction

